Apollo endosurgery announces preliminary third quarter 2021 financial results and provides business updates

Revenue expected between $16.0 million and $16.4 million third consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30% submitted a de novo 510(k) classification request to fda for apollo esg™ for weight loss and apollo revise™ for prior bariatric surgery revisions principal investigators expected to present primary efficacy and safety endpoints from merit study in late october austin, tx / accesswire / october 7, 2021 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today preliminary unaudited financial results and corporate updates for the third quarter ended september 30, 2021, including anticipated revenue in the range of $16.0 million to $16.4 million and anticipated revenue growth in the range of 25% to 28% compared to third quarter 2020. preliminary, unaudited third quarter 2021 financial results total revenue $16.0 million to $16.4 million gross margin 54% to 56% operating loss $(4.1) million to $(5.2) million net loss $(6.1) million to $(7.3) million non-gaap adjusted ebitda $(2.1) million to $(3.0) million "we continue to successfully deliver against the priorities that we committed to early this year: specifically, to energize our business and drive near-term growth while laying the foundation for additional large-scale opportunities," said chas mckhann, president and ceo.
APEN Ratings Summary
APEN Quant Ranking